Voyager Therapeutics IncNASDAQ:VYGR
- LAST PRICE7.8200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots7.8000/ 1
- Ask / Lots7.8200/ 2
- Open / Previous Close0.0000 / 7.8200
- Day Range---
- 52 Week Range
- Volume100
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VYGR |
|---|---|---|
| 09:32 ET | 4664 | 7.98 |
| 09:34 ET | 1113 | 7.99 |
| 09:39 ET | 100 | 7.995 |
| 09:45 ET | 100 | 7.99 |
| 09:50 ET | 235 | 7.975 |
| 09:56 ET | 1295 | 7.96 |
| 09:57 ET | 1222 | 7.99 |
| 10:01 ET | 1375 | 7.97 |
| 10:03 ET | 100 | 7.98 |
| 10:06 ET | 700 | 8.005 |
| 10:08 ET | 200 | 8.01 |
| 10:12 ET | 2003 | 7.99 |
| 10:14 ET | 300 | 8.005 |
| 10:21 ET | 400 | 8.01 |
| 10:24 ET | 100 | 8.025 |
| 10:26 ET | 3599 | 8.025 |
| 10:28 ET | 100 | 8.01 |
| 10:33 ET | 362 | 7.99 |
| 10:35 ET | 1989 | 8 |
| 10:37 ET | 319 | 8.02 |
| 10:44 ET | 638 | 8.03 |
| 10:46 ET | 400 | 8.044 |
| 10:48 ET | 884 | 8.045 |
| 10:53 ET | 200 | 8.045 |
| 10:57 ET | 1300 | 8.07 |
| 11:04 ET | 708 | 8.075 |
| 11:06 ET | 730 | 8.095 |
| 11:08 ET | 600 | 8.07 |
| 11:13 ET | 1000 | 8.06 |
| 11:15 ET | 100 | 8.065 |
| 11:20 ET | 1417 | 8.07 |
| 11:24 ET | 625 | 8.03 |
| 11:33 ET | 108 | 8.02 |
| 11:42 ET | 100 | 8.01 |
| 11:45 ET | 819 | 8.01 |
| 11:47 ET | 900 | 8.03 |
| 11:51 ET | 100 | 8.04 |
| 11:54 ET | 300 | 8.04 |
| 11:56 ET | 319 | 8.04 |
| 11:58 ET | 1912 | 8.03 |
| 12:03 ET | 400 | 8.04 |
| 12:09 ET | 3623 | 8.05 |
| 12:16 ET | 1120 | 8.03 |
| 12:18 ET | 800 | 8.05 |
| 12:20 ET | 3389 | 8.0403 |
| 12:21 ET | 300 | 8.05 |
| 12:25 ET | 1200 | 8.04 |
| 12:30 ET | 100 | 8.06 |
| 12:32 ET | 100 | 8.04 |
| 12:34 ET | 200 | 8.04 |
| 12:36 ET | 100 | 8.04 |
| 12:38 ET | 100 | 8.05 |
| 12:43 ET | 100 | 8.04 |
| 12:50 ET | 100 | 8.04 |
| 12:54 ET | 794 | 8.05 |
| 12:56 ET | 100 | 8.04 |
| 12:57 ET | 532 | 8.035 |
| 01:01 ET | 200 | 8.0391 |
| 01:03 ET | 161 | 8.03 |
| 01:12 ET | 100 | 8.0352 |
| 01:14 ET | 400 | 8.04 |
| 01:15 ET | 300 | 8.04 |
| 01:19 ET | 300 | 8.04 |
| 01:24 ET | 200 | 8.04 |
| 01:26 ET | 428 | 8.04 |
| 01:32 ET | 302 | 8.04 |
| 01:35 ET | 100 | 8.035 |
| 01:39 ET | 900 | 8.035 |
| 01:50 ET | 200 | 8.04 |
| 01:53 ET | 5832 | 8.04 |
| 02:02 ET | 200 | 8.04 |
| 02:13 ET | 100 | 8.03 |
| 02:20 ET | 121 | 8.04 |
| 02:22 ET | 1649 | 8.03 |
| 02:27 ET | 4611 | 8.03 |
| 02:31 ET | 7631 | 8.025 |
| 02:33 ET | 300 | 8.025 |
| 02:36 ET | 6099 | 8.02 |
| 02:38 ET | 3270 | 7.99 |
| 02:40 ET | 1121 | 7.965 |
| 02:42 ET | 399 | 7.96 |
| 02:45 ET | 1600 | 7.975 |
| 02:47 ET | 323 | 7.97 |
| 02:49 ET | 200 | 7.96 |
| 02:51 ET | 160 | 7.96 |
| 02:54 ET | 1050 | 7.95 |
| 02:56 ET | 100 | 7.94 |
| 02:58 ET | 2000 | 7.945 |
| 03:00 ET | 6597 | 7.9409 |
| 03:02 ET | 1321 | 7.935 |
| 03:03 ET | 1701 | 7.95 |
| 03:12 ET | 592 | 7.935 |
| 03:14 ET | 200 | 7.93 |
| 03:16 ET | 1473 | 7.945 |
| 03:18 ET | 281 | 7.95 |
| 03:20 ET | 1199 | 7.945 |
| 03:23 ET | 400 | 7.94 |
| 03:30 ET | 1501 | 7.925 |
| 03:32 ET | 4075 | 7.93 |
| 03:36 ET | 300 | 7.935 |
| 03:38 ET | 100 | 7.935 |
| 03:41 ET | 1138 | 7.92 |
| 03:45 ET | 1647 | 7.9 |
| 03:50 ET | 700 | 7.885 |
| 03:52 ET | 600 | 7.885 |
| 03:54 ET | 601 | 7.885 |
| 03:56 ET | 8081 | 7.84 |
| 03:57 ET | 3083 | 7.83 |
| 03:59 ET | 4055 | 7.82 |
Jun 13, 2024
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences, from 4:01PM ET on Thursday Jun 13, 2024 by Dow Jones
4:01PM ET on Thursday Jun 13, 2024 by Dow JonesDJ Voyager Therapeutics Taps Nathan Jorgensen as Finance Chief, from 7:16AM ET on Thursday Jun 13, 2024 by Dow Jones
7:16AM ET on Thursday Jun 13, 2024 by Dow JonesPress Release: Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer, from 7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
7:00AM ET on Thursday Jun 13, 2024 by Dow JonesVoyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer, from 7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Voyager Therapeutics Inc | 425.4M | -43.2x | --- |
Revance Therapeutics Inc | 245.5M | -0.7x | --- |
Ginkgo Bioworks Holdings Inc | 707.8M | -0.7x | --- |
Coherus BioSciences Inc | 181.3M | -2.0x | --- |
Puma Biotechnology Inc | 142.8M | 9.2x | --- |
Vanda Pharmaceuticals Inc | 357.3M | -72.6x | -37.98% |
Company Information
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
Contact Information
- Headquarters
- 75 Hayden AvenueLEXINGTON, MA, United States 02421
- Phone
- 857-259-5340
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Michael Higgins
- President, Chief Executive Officer, Director
- Alfred Sandrock
- Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
- Nathan Jorgensen
- Chief Operating Officer
- Robin Swartz
- Chief Scientific Officer
- Todd Carter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $425.4M |
|---|---|
Revenue (TTM) | $119.0M |
Shares Outstanding | 54.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $-0.18 |
Book Value | $5.37 |
P/E Ratio | -43.2x |
Price/Sales (TTM) | 3.6 |
Price/Cash Flow (TTM) | 280.2x |
Operating Margin | -14.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
